Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of “Moderate Buy” from Analysts

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has been assigned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $23.6667.

A number of analysts recently weighed in on the stock. HC Wainwright raised their target price on shares of Kyverna Therapeutics from $10.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, October 27th. William Blair began coverage on Kyverna Therapeutics in a research note on Wednesday, August 20th. They set an “outperform” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Wednesday, November 5th. Finally, Wells Fargo & Company upped their target price on Kyverna Therapeutics from $27.00 to $31.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th.

Kyverna Therapeutics Trading Up 9.5%

Shares of NASDAQ KYTX opened at $7.00 on Wednesday. Kyverna Therapeutics has a twelve month low of $1.78 and a twelve month high of $8.45. The firm has a 50-day moving average of $6.02 and a two-hundred day moving average of $4.14. The company has a market capitalization of $302.75 million, a price-to-earnings ratio of -1.90 and a beta of 3.79.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.03. As a group, research analysts predict that Kyverna Therapeutics will post -3.29 earnings per share for the current year.

Institutional Investors Weigh In On Kyverna Therapeutics

A number of large investors have recently made changes to their positions in the company. Capital Advisors Inc. OK purchased a new stake in shares of Kyverna Therapeutics in the 3rd quarter valued at approximately $60,000. Phoenix Wealth Advisors acquired a new stake in Kyverna Therapeutics during the 2nd quarter valued at $32,000. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Kyverna Therapeutics in the second quarter valued at $37,000. Qube Research & Technologies Ltd acquired a new stake in shares of Kyverna Therapeutics in the second quarter worth $43,000. Finally, Ethic Inc. purchased a new position in shares of Kyverna Therapeutics during the second quarter valued at $56,000. Institutional investors and hedge funds own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.